Literatur: Warfarin

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Warfarin

  • 1. Patel MR, Mahaffey KW, Garg J, et al, “Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation,” N Engl J Med, 2011, 365(10):883-91. [PubMed 21830957]
  • 2. Connolly SJ, Ezekowitz MD, Yusuf S, et al, “Dabigatran Versus Warfarin in Patients With Atrial Fibrillation,” N Engl J Med, 2009, 361(12):1139-51 [PubMed 19717844]
  • 3. Eikelboom JW, Wallentin L, Connolly SJ, et al, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial,” Circulation, 2011, 123(21):2363-72. [PubMed 21576658]
  • 4. Ezekowitz MD, Reilly PA, Nehmiz G, et al, “Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study),” Am J Cardiol, 2007, 100(9):1419-26. [PubMed 17950801]
  • 5. Wallentin L, Yusuf S, Ezekowitz MD, et al, “Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial,” Lancet, 2010, 376(9745):975-83. [PubMed 20801496]
  • 6. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493. [PubMed 17693178]
  • 7. Lidell C, Svedberg LE, Lindell P, et al, "Clopidogrel and Warfarin: Absence of Interaction in Patients Receiving Long-Term Anticoagulant Therapy for Nonvalvular Atrial Fibrillation," Thromb Haemost, 2003, 89(5):842-6. [PubMed 12719782]
  • 8. Christopher B. Granger, M.D., John H. Alexander, M.D., M.H.S., John J.V. McMurray, M.D., et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365:981-992 [PubMed 1107039]
  • 9. Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood 2011; 117:5044. [PubMed 21415266]
  • 10. Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med 2009; 76 Suppl 4:S37. [PubMed 19880835]
  • 11. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74:606. [PubMed 8584992]
  • 12. Otley CC. Continuation of medically necessary aspirin and warfarin during cutaneous surgery. Mayo Clin Proc 2003; 78:1392. [PubMed 14601698]
  • 13. Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol 2003; 48:233. [PubMed 12582394]
  • 14. Nelms JK, Wooten AI, Heckler F. Cutaneous surgery in patients on warfarin therapy. Ann Plast Surg 2009; 62:275. [PubMed 19240524]
  • 15. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122:40. [PubMed 7985894]
  • 16. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112:423. [PubMed 2178534]
  • 17. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343:886. [PubMed 7908358]
  • 18. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633. [PubMed 8782752]
  • 19. Larson BJ, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005; 127:922. [PubMed 15764777]
  • 20. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110:1658. [PubMed 15364803]
  • 21. Carter CJ. The pathophysiology of venous thrombosis. Prog Cardiovasc Dis 1994; 36:439. [PubMed 8184097]
  • 22. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164:1319. [PubMed 15226166]
  • 23. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168:63. [PubMed 18195197]
  • 24. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94:528. [PubMed 16268467]
  • 26. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007; 146:184. [PubMed 17283349]
  • 27. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297. [PubMed 19721017]
  • 28. Agarwal S, Hachamovitch R, Menon V. Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation: A Meta-analysis. Arch Intern Med 2012. [PubMed 22450212]
  • 29. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700. [PubMed 17679129]
  • 30. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167:239. [Pubmed 17296878]
  • 31. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689. [Pubmed 17515465]
  • 32. Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011; 155:653. [Pubmed 22084331]
  • 33. Kearon C et al, Vergleich einer Warfarin–Therapie von niedriger Intensität mit einer Warfarin–Therapie von konventioneller Intensität zur Langzeitprävention von rezidivierenden venösen Thromboembolien N Engl J Med 2003; 349: 631 - 9. [Pubmed 12917299]
  • 34. Jaffer AK, Brotman DJ, Bash LD, et al. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med 2010; 123:141. [Pubmed 20103023]
  • 35. Larson BJ, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005; 127:922. [Pubmed 15764777]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun